Drug Trial Radar · NCT06938880
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
May 20, 2025
Primary completion
May 2027
Study completion Apr 2028
Sponsor
- Lead sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is designed to assess the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of the combination of ZGGS18 and ZG005 in patients with advanced solid tumors, including advanced cervical cancer, hepatocellular carcinoma, neuroendocrine cancer, and lung cancer.
Conditions
- Advanced Solid Tumor
Interventions
ZGGS18 for InjectionBiological
Intravenous infusion
ZG005 for InjectionBiological
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limited toxicity(DLT)Time frame: up to 21 days
- Adverse Event (AE)Time frame: Up to 2 years
- Maximum tolerated dose(MTD)Time frame: Up to 1 years
- Recommended phase II dose(RP2D)Time frame: Up to 1 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.